Advertisement
U.S. markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.72-0.01 (-0.14%)
At close: 04:00PM EDT
10.67 -0.05 (-0.47%)
After hours: 07:20PM EDT

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200
https://www.inovio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees122

Key Executives

NameTitlePayExercisedYear Born
Dr. Jacqueline E. Shea Ph.D.CEO, President & Director1.08MN/A1966
Mr. Peter D. KiesChief Financial Officer688.72kN/A1963
Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer673.59kN/A1967
Thomas HongManager of Investor RelationsN/AN/AN/A
Mr. Robert L. Crotty J.D.General Counsel & Chief Compliance OfficerN/AN/A1974
Mr. E. J. Brandreth MBASenior Vice President of Quality AssuranceN/AN/AN/A
Dr. Jeffrey SkolnikSenior Vice President of Clinical DevelopmentN/AN/AN/A
Mr. Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply ManagementN/AN/AN/A
Mr. Stephen Kemmerrer M.B.A., P.E.Senior Vice President of Engineering DevelopmentN/AN/AN/A
Mr. Shawn D. Bridy M.A., M.B.A.Senior Vice President of Business DevelopmentN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate Governance

Inovio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.